Nexus Energy Services, Inc. (USOTC:IBGR)
Historical Stock Chart
5 Years : From Oct 2012 to Oct 2017
PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") announced today that Dr. James Carlson has accepted a position on the Board of Directors for the Company, and will also serve as the Chairman for the Medical Advisory Board.
Dr. Carlson received a Bachelor of Science degree in Biochemistry and Cellular Physiology from Cornell University. He additionally received a Doctorate of Medicine degree from the New York College of Osteopathic Medicine in Old Westbury, New York. Dr. Carlson was the chief resident at Delaware Valley Medical Center in Langhorne, Pennsylvania, and later obtained a Master's of Business, with an emphasis on Healthcare Economics and Physician Practice Management from Regis University in Denver, Colorado. He also holds a Juris Doctorate in Law, with an emphasis in Healthcare law from Concord University School of Law, located in Los Angeles, California. Dr. Carlson's website can be found at: www.drjamescarlson.com
Dr. Carlson is the author of "Genocide: How Your Doctor's Dietary Ignorance Will Kill You," a controversial book detailing the shortcomings of the medical community in the United States while promoting a much healthier diet. He is the host of "Ultimate Wellness with Dr. James Carlson," a radio and video commentary program promoting good dietary practices and commenting on the shortcomings of the medical community. This program can be viewed on his YouTube channel, DreamweaverHouse.
Dr. Carlson stated, "I am honored to be working with PharmStar and bringing this important technology to market. By eliminating acid and sodium with Aquaprin, Howard has eliminated everything that is wrong with the way we take aspirin. It's an unbelievable product, and I can't wait to get the Medical Advisory Board fired up and educating the medical community and the rest of the world about this superior pain reliever."
CEO Howard Phykitt commented, "What an honor it is to announce Dr. Carlson as a member of the Company's Board of Directors. He is a physician, a businessman and a Health Care attorney, and is passionate about his work. He uses his unique talents to explain common sense ideas about diets and wellness programs, and will bring a lot of energy to the Company. We are proud he has come aboard."
Dr. Carlson will be speaking about and promoting Aquaprin through his YouTube channel video productions, and whenever he is speaking directly to the medical community.
About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin™. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin™'s unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.
PharmStar initially plans to sell Aquaprin™ directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability; shelf life testing and quality control research has been completed. PharmStar's headquarters are located in Wilson, NC.
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
PharmStar Pharmaceuticals, Inc.
919-794-7000 (During message, press 5)